1 Jackson, L. A. et al. An mRNA Vaccine against SARS-CoV-2 – Preliminary Report. New Engl J Med (2020)
doi:10.1056/nejmoa2022483.
2 Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020).
3 Houseley, J. & Tollervey, D. The Many Pathways of RNA Degradation. Cell 136, 763–776 (2009).
4 Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov 17, 261–279 (2018).
5 Chen, N. et al. RNA sensors of the innate immune system and their detection of pathogens. Iubmb Life 69, 297–304 (2017).
6 Jia, J. et al. Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy. Frontiers Oncol 8, 404 (2018).
7 Khalil, I. A., Younis, M. A., Kimura, S. & Harashima, H. Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids. Biological Pharm Bulletin 43, 584–595 (2020).
8 Rijkers, G. T. et al. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Nato Adv Sci Inst Se 9, 848 (2021).
9 Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep-uk 7, 252 (2017).
10 Hsieh, C.-L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501–1505 (2020).
11 Heyward, J. T., Klimas, R. A., Stapp, M. D. & Obijeski, J. F. The rapid concentration and purification of influenza virus from allantoic fluid. Arch Virol 55, 107–119 (1977).
12 McLean, K. A., Goldin, S., Nannei, C., Sparrow, E. & Torelli, G. The 2015 global production capacity of seasonal and pandemic influenza vaccine. Vaccine 34, 5410–5413 (2016).
13 Boerner, L. K. The Flu Shot and the Egg. Acs Central Sci 6, 89–92 (2020).
14 Divino, V. et al. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season. Vaccine 38, 6334–6343 (2020).
15 McNeil, M. M. Vaccine-Associated Anaphylaxis. Curr Treat Options Allergy 6, 297–308 (2019).
16 Greenhawt, M. et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract (2021)
doi:10.1016/j.jaip.2021.06.006.
17 Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
18 Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).
20 WHO. WHO COVID-19 weekly report. (2020).
21 Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New Engl J Med 384, 403–416 (2020).
22 Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New Engl J Med 383, 2603–2615 (2020).
23. Dagan, N. et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New Engl J Med 384, 1412–1423 (2021).
24 Bernal, J. L. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New Engl J Med 385, 585–594 (2021).
25 Sanderson, K. COVID vaccines protect against Delta, but their effectiveness wanes. Nature (2021) doi:10.1038/d41586-021-02261-8.
26 Pichla-Gollon, S. L. et al. Effect of Preexisting Immunity on an Adenovirus Vaccine Vector: In Vitro Neutralization Assays Fail To Predict Inhibition by Antiviral Antibody In Vivo. J Virol 83, 5567–5573 (2009).
27 Diaz, G. A. et al. Myocarditis and Pericarditis After Vaccination for COVID-19. Jama 326, 1210–1212 (2021).
28 Pushparajah, D. et al. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Adv Drug Deliver Rev 170, 113–141 (2021).
29 Klein, N. P. et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Jama 326, (2021).
30 Thomas, S. J. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New Engl J Med (2021)
doi:10.1056/nejmoa2110345.
31 Keesing, F. et al. Impacts of biodiversity on the emergence and transmission of infectious diseases. Nature 468, 647–652 (2010).
32 Gibb, R. et al. Zoonotic host diversity increases in human-dominated ecosystems. Nature 584, 398–402 (2020).
33 Awasthi, S. et al. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol 4, eaaw7083 (2019).
34 Aliprantis, A. O. et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vacc Immunother 17, 1–14 (2020).
35 Meyer, M. et al. Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease. J Infect Dis 217, 451–455 (2017).
36 Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511–1520 (2017).
37 Bloom, K., Berg, F. van den & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther 28, 117–129 (2021).
38 Pattnaik, A., Sahoo, B. R. & Pattnaik, A. K. Current Status of Zika Virus Vaccines: Successes and Challenges. Nato Adv Sci Inst Se 8, 266 (2020).